AstraZeneca Shares Rebound After Bristol Myers Deal Rumors Quashed
Senior source tells Reuters there are no talks between AstraZeneca and Bristol Myers Squibb, ending $400B merger rumors and lifting shares.
/ 83 items
#XY News-Driven Stocks↓
P&G Buys Thorne for $3.8 Billion to Boost Health and Wellness Business
CEO announces the deal on CNBC.
AstraZeneca and Bristol Myers Squibb Explore $400 Billion Pharma Merger
Cancer drugs drive sales for both, with direct overlaps like Imfinzi and Opdivo raising antitrust risks.
BioAge Labs Plunges Over 60% After Novo’s ZEUS Trial Failure — Citi Says the Sell-Off Is Overdone
BioAge Labs shares fell over 60% after Novo Nordisk’s ZEUS trial failed to cut MACE. Citi says the sell-off is excessive despite negative ASCVD impact.
Private-Equity Firm KKR Near Agreement to Take Medical-Device Maker Integer Holdings Private
KKR nears deal to take Integer Holdings private at $127/share. Announcement possible next week; values the medical-device CDMO at ~$4.3B.
FDA Raises Serious Doubts Over Replimune’s RP1 Melanoma Therapy Ahead of Key Panel
FDA briefing docs criticize Replimune’s RP1 trial data, raising doubts over effectiveness and sending shares down ahead of Thursday’s panel.